Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 rozanolixizumab study in adults with MOG antibody-associated disease
2021-000352-19Phase 3Active
- Sponsor
- UCB
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rozanolixizumab in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) (3 arms), sponsored by UCB. Started Sep 2021; status: active.
02
Drugs
rozanolixizumab
03
Conditions
myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
Beyond the preview
Go deeper on 2021-000352-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000352-19.